Adagio Medical Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.6M
- Price
- $0.1338
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.04%
- Volume
- 1.6M
About
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Quick stats
Shares outstanding27.2M
Computed float19.0M
Float / shares69.8%
Cash runway (months)1.9
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002006986
Websitehttps://adagiomedical.com
AI Summary
AI-generated1/13
majormixedrestructuring
Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value
Adagio Medical's board initiated a formal strategic alternatives process that may include an acquisition, merger, or business combination, with no timetable set and no assurance of a transaction.
In parallel, the company is implementing a workforce reduction to align its cost structure with prioritized programs while continuing to advance the PMA application for its vCLAS Ventricular Ablation System.
Adagio reported approximately $7.7 million in preliminary unaudited cash, equivalents, and marketable securities as of June 30, 2026 — a thin liquidity position that underscores the urgency of the strategic review.
Red flags
- Only ~$7.7M in cash and investments as of June 30, 2026 — limited runway
- Strategic alternatives process carries no assurance of a transaction or attractive terms
- Workforce reduction suggests cash preservation and possible program prioritization